RevBio, Inc., announced that it has received investigational device exemption (IDE) approval from the FDA to conduct a multi-center randomized controlled pivotal clinical trial to use TETRANITE(R) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results